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Abstract
Currently  the World  Health  Organization only  recommend fluoroquinolones for  people  with
presumed drug-sensitive tuberculosis (TB) who cannot take standard first-line drugs. However,
use of fluoroquinolones could shorten the length of treatment and improve other outcomes in
these people. This review summarises the effects of fluoroquinolones in first-line regimens in
people with presumed drug-sensitive TB. To assess fluoroquinolones as substitute or additional
components in antituberculous drug regimens for drug-sensitive TB. We searched the Cochrane
Infectious Diseases Group Specialized Register; CENTRAL (The Cochrane Library 2013, Issue 1);
MEDLINE;  EMBASE;  LILACS;  Science Citation Index;  Databases of  Russian Publications;  and
metaRegister of Controlled Trials up to 6 March 2013. Randomized controlled trials (RCTs) of
antituberculous  regimens  based  on  rifampicin  and  pyrazinamide  and  containing
fluoroquinolones  in  people  with  presumed  drug-sensitive  pulmonary  TB.  Two  authors
independently applied inclusion criteria, assessed the risk of bias in the trials, and extracted
data. We used the risk ratio (RR) for dichotomous data and the fixed-effect model when it was
appropriate to combine data and no heterogeneity was present. We assessed the quality of
evidence using the GRADE approach. We identified five RCTs (1330 participants) that met the
inclusion  criteria.  None of  the  included trials  examined regimens of  less  than six  months
duration. Fluoroquinolones added to standard regimensA single trial (174 participants) added
levofloxacin to the standard first-line regimen. Relapse and treatment failure were not reported.
For death, sputum conversion, and adverse events we are uncertain if there is an effect (one
trial,  174 participants,  very low quality  evidence for  all  three outcomes).  Fluoroquinolones
substituted for  ethambutol  in standard regimens Three trials  (723 participants)  substituted
ethambutol with moxifloxacin, gatifloxacin, and ofloxacin into the standard first-line regimen.
For relapse, we are uncertain if there is an effect (one trial, 170 participants, very low quality
evidence). No trials reported on treatment failure. For death, sputum culture conversion at eight
weeks, or serious adverse events we do not know if there was an effect (three trials, 723
participants, very low quality evidence for all three outcomes). Fluoroquinolones substituted for
isoniazid in standard regimens A single trial  (433 participants) substituted moxifloxacin for
isoniazid.  Treatment  failure  and  relapse  were  not  reported.  For  death,  sputum  culture
conversion, or serious adverse events the substitution may have little or no difference (one trial,
433 participants, low quality evidence for all three outcomes). Fluoroquinolines in four month
regimensSix trials are currently in progress testing shorter regimens with fluoroquinolones.
Ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin have been tested in RCTs of standard
first-line regimens based on rifampicin and pyrazinamide for treating drug-sensitive TB. There is
insufficient  evidence  to  be  clear  whether  addition  or  substitution  of  fluoroquinolones  for
ethambutol or isoniazid in the first-line regimen reduces death or relapse, or increases culture
conversion at eight weeks. Much larger trials with fluoroquinolones in short course regimens of
four months are currently in progress.
